FI78691B - Foerfarande foer framstaellning av i position 3-substituerade pyridazinderivat, vilka inverkar pao det centrala nervsystemet. - Google Patents
Foerfarande foer framstaellning av i position 3-substituerade pyridazinderivat, vilka inverkar pao det centrala nervsystemet. Download PDFInfo
- Publication number
- FI78691B FI78691B FI840323A FI840323A FI78691B FI 78691 B FI78691 B FI 78691B FI 840323 A FI840323 A FI 840323A FI 840323 A FI840323 A FI 840323A FI 78691 B FI78691 B FI 78691B
- Authority
- FI
- Finland
- Prior art keywords
- formula
- compound
- converted
- alk
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Claims (8)
1. Förfarande för framställning av nya terapeutiskt användbara pyridazlnderivat med formeln Ib och deras far-5 maceutiskt godtagbara syraadditionssalter R2^^ /R;3 R1 \\ /) n NH2 (Ib) 10 \ β Alk-R. 4 1 vilken formal är väte eller lägre alkyl, eller fenyl, som kan vara 15 monosubstltuerad mad halogen, nitro, lägre alkyl, lägre alkoxi, hydroxl eller trifluormetyl, eller disubstituerad med halogen, eller naftyl, cyklohexyl, 2-tienyl eller 3-tlenyl, R2 är väte, lägre alkyl eller fenyl,
20 Rj är väte, lägre alkyl eller fenyl, Alk är -(CHj)n-, väri n är ett heitai 2, 3 eller 4, eller -CHjCsC-, R4 är -C00H, -COO-alkyl, -C0NH2 eller -CaN, och 3^ är en anjon av en oorganisk syra, företrädesvis en 25 anjon av klorvätesyra eller bromvätesyra, känne-t e c k n a t därav, att A) för framställning av en förening med formeln Ib, väri Alk är -(CH2)n-, väri n är 2, 3 eller 4, 1. omsättes ett 3-klorpyridazlnderlvat med formeln 30 R2 ^___^ R3 : : R1 -C1 N—N (I) 1 väri R2, R2 och R3 har ovan angivna betydelse, vid ref- 22 73691 luxeringstemperaturen med ett överskott av hydrazinhydrat, varvid man erhäller en pyridazinförening med formeln, och R2 R3
2. Förfarande enligt patentkravet 1, kanne-t e c k n a t därav, att 1 steg A 4) förenlngen med formeln Ib, väri R4 ar -COO-alkyl, förtvälas till en förenlng med formeln Ib, väri R4 ar -C00H. 15
3. Förfarande enligt patentkravet 2, kanne- t e c k n a t därav, att förtvälningen utföres under sura betingelser.
4. Förfarande enligt patentkravet 3, kanne- t e c k n a t därav, att förtvälningen utföres genom upp- 20 hettning med en syra, säsom klorvätesyra eller bromväte-syra i ättiksyra vid en temperatur av 20-100°C.
5. Förfarande enligt patentkravet 1, kanne-t e c k n a t därav, att i steg A 3) omvandlas en före-ning med formeln lb, vari R4 ar -COO-alkyl eller cyano, 25 till en förenlng med formeln lb, vari R4 är en karboxamid-grupp, vilken reaktion ästadkommes medelst ammoniumhydr-oxid i en alkanol, säsom metanol.
5 Ri—^ ^-nh-nh2 (II) i vilken formel Rx, R2 och R3 har ovan angivna betydelse, 10 och 2. den sälunda erhällna förenlngen med formeln II omvandlas tili ett motsvarande 3-aminopyridazinderivat med formeln lii genom katalytisk hydrogenering, varvid säsom katalysator kan användas tili exempel Raney-nickel,
15 R2 R3 Rl“Ö“ NH2 UH» 20 1 vilken formel Rx, R2 och R3 har ovan angivna betydelse, och 3. den sälunda erhällna förenlngen med formeln III omsättes 1 ett inert lösningsmedel vid en temperatur av 25 50-100°C med en UJ-halogenerad förenlng med formeln X-Alk-R4, väri X är halogen och R4 är -COO-alkyl eller cyano för erhällande av en förenlng med formeln Ib, väri R4 Är -COO-alkyl eller cyano, och 4. on s& önskas omvandlas den erhälinä förenlngen 30 med formeln Ib genom förtvälning tili en förenlng med formeln Ib, väri R4 är -COOH, eller medelst ammoniak tili en förenlng med formeln Ib, väri R4 är karboxamido, eller om sä önskas omvandlas en förenlng med formeln Ib, väri R4 är cyano, genom varsam hydrolys tili en motsvarande före-35 nlng, väri R4 är karboxamido, och 23 78691 5. om sä önskas, omvandlas den erhällna förenlngen till ett farmaceutiskt godtagbart salt, eller B) för framstailning av en förenlng med formeln lb, väri Aik är -CH2-CsC-, 5 1) karboniseras en motsvarande pyridazin, vilken är substituerad i 3-ställningen med gruppen -NH-Alk-, vari Aik är en acetylengrupp, och 2. om sä önskas, omvandlas den erhälinä förenlngen med formeln lb till ett farmaceutiskt godtagbart syraad- 10 ditionssalt.
6. Förfarande enligt patentkravet 1, k ä n nets c k n a t därav, att en förenlng med formeln lb, vari
30 R4 är cyano, omvandlas till en förenlng med formeln lb, vari R4 är karboxamido, medelst vattenfri myrsyra i när-varo av klorvätegas.
7. Förfarande enligt patentkravet 1, k ä n nets c k n a t därav, att man använder ett utgängsämne med 35 formeln III, vari Rj ar p-klorfenyl, och R2 och R3 ar vä-
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8301234A FR2540113A1 (fr) | 1983-01-27 | 1983-01-27 | Acides derives de la pyridazine actifs sur le systeme nerveux central |
FR8301234 | 1983-01-27 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI840323A0 FI840323A0 (fi) | 1984-01-26 |
FI840323A FI840323A (fi) | 1984-07-28 |
FI78691B true FI78691B (fi) | 1989-05-31 |
FI78691C FI78691C (sv) | 1989-09-11 |
Family
ID=9285330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI840323A FI78691C (sv) | 1983-01-27 | 1984-01-26 | Förfarande för framställning av i position 3-substituerade pyridazinde rivat, vilka inverkar på det centrala nervsystemet |
Country Status (27)
Country | Link |
---|---|
US (1) | US4721711A (sv) |
EP (1) | EP0117779B1 (sv) |
JP (1) | JPS59141564A (sv) |
KR (1) | KR910000638B1 (sv) |
AR (1) | AR240045A1 (sv) |
AT (1) | ATE48417T1 (sv) |
AU (2) | AU2372984A (sv) |
CA (1) | CA1238637A (sv) |
DD (1) | DD220026A5 (sv) |
DE (1) | DE3480653D1 (sv) |
DK (1) | DK162985C (sv) |
ES (1) | ES529081A0 (sv) |
FI (1) | FI78691C (sv) |
FR (1) | FR2540113A1 (sv) |
HU (1) | HU193890B (sv) |
IE (1) | IE57054B1 (sv) |
IL (1) | IL70756A (sv) |
MA (1) | MA20018A1 (sv) |
NO (1) | NO840313L (sv) |
NZ (1) | NZ206945A (sv) |
OA (1) | OA07644A (sv) |
PH (1) | PH21162A (sv) |
PL (1) | PL142340B1 (sv) |
PT (1) | PT77993B (sv) |
SG (1) | SG93690G (sv) |
YU (1) | YU14284A (sv) |
ZA (1) | ZA84502B (sv) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2540113A1 (fr) * | 1983-01-27 | 1984-08-03 | Sanofi Sa | Acides derives de la pyridazine actifs sur le systeme nerveux central |
DE3664772D1 (en) * | 1985-01-14 | 1989-09-07 | Boehringer Ingelheim Kg | 12-amino pyridazinoû4',5':3,4¨pyrroloû2,1-a¨isoquinolines, process for their preparation and use |
US5082939A (en) * | 1987-01-08 | 1992-01-21 | I.S.F. Societa Per Azioni | Pyridazine derivatives |
US5106973A (en) * | 1987-11-23 | 1992-04-21 | Janssen Pharmaceutica N.V. | Pyridzainamine derivatives |
US5656631A (en) * | 1989-02-07 | 1997-08-12 | Sanofi | Pyridazine derivatives |
FR2663326B2 (fr) * | 1989-11-17 | 1992-10-16 | Sanofi Sa | Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant. |
FR2668151A1 (fr) * | 1990-10-23 | 1992-04-24 | Rhone Poulenc Agrochimie | Composes a groupe triazolopyridazine leurs preparations et compositions herbicides les contenant. |
FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
CN1038249C (zh) * | 1991-08-28 | 1998-05-06 | 罗姆和哈斯公司 | 含有二氢哒嗪酮及其相关化合物的杀菌组合物 |
US20100210590A1 (en) * | 1995-09-27 | 2010-08-19 | Northwestern University | Compositions and treatments for seizure-related disorders |
US20030176437A1 (en) * | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
BRPI0517947A (pt) | 2004-11-02 | 2008-10-21 | Univ Northwestern | composto de piridazina, composições e métodos |
WO2006050359A2 (en) * | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
AU2007243280A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
EP2015750A2 (en) * | 2006-04-28 | 2009-01-21 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
CA2650704A1 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Salts of pyridazine compounds |
US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
US8207205B2 (en) | 2008-04-21 | 2012-06-26 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2010033626A1 (en) * | 2008-09-19 | 2010-03-25 | Institute For Oneworld Health | Compounds, compositions and methods comprising imidazole and triazole derivatives |
US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2510998B1 (fr) * | 1981-08-07 | 1986-01-10 | Sanofi Sa | Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent |
FR2510997A1 (fr) * | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
FR2540113A1 (fr) * | 1983-01-27 | 1984-08-03 | Sanofi Sa | Acides derives de la pyridazine actifs sur le systeme nerveux central |
CA1218655A (en) * | 1983-01-28 | 1987-03-03 | Kathleen Biziere | Process for the preparation of pyridazine derivatives having a psychotropic action |
-
1983
- 1983-01-27 FR FR8301234A patent/FR2540113A1/fr active Granted
-
1984
- 1984-01-18 CA CA000445481A patent/CA1238637A/en not_active Expired
- 1984-01-20 PH PH30135A patent/PH21162A/en unknown
- 1984-01-20 AR AR295532A patent/AR240045A1/es active
- 1984-01-23 IL IL70756A patent/IL70756A/xx unknown
- 1984-01-23 ES ES529081A patent/ES529081A0/es active Granted
- 1984-01-23 IE IE149/84A patent/IE57054B1/en not_active IP Right Cessation
- 1984-01-23 ZA ZA84502A patent/ZA84502B/xx unknown
- 1984-01-23 PT PT77993A patent/PT77993B/pt not_active IP Right Cessation
- 1984-01-24 AU AU23729/84A patent/AU2372984A/en not_active Abandoned
- 1984-01-25 EP EP84400156A patent/EP0117779B1/fr not_active Expired
- 1984-01-25 DE DE8484400156T patent/DE3480653D1/de not_active Expired - Fee Related
- 1984-01-25 AT AT84400156T patent/ATE48417T1/de not_active IP Right Cessation
- 1984-01-26 FI FI840323A patent/FI78691C/sv not_active IP Right Cessation
- 1984-01-26 HU HU84331A patent/HU193890B/hu not_active IP Right Cessation
- 1984-01-26 DD DD84259650A patent/DD220026A5/de not_active IP Right Cessation
- 1984-01-26 OA OA58216A patent/OA07644A/xx unknown
- 1984-01-26 KR KR1019840000335A patent/KR910000638B1/ko not_active IP Right Cessation
- 1984-01-26 MA MA20239A patent/MA20018A1/fr unknown
- 1984-01-26 NZ NZ206945A patent/NZ206945A/en unknown
- 1984-01-26 NO NO840313A patent/NO840313L/no unknown
- 1984-01-27 DK DK038984A patent/DK162985C/da active
- 1984-01-27 PL PL1984245931A patent/PL142340B1/pl unknown
- 1984-01-27 JP JP59013234A patent/JPS59141564A/ja active Pending
- 1984-01-27 YU YU00142/84A patent/YU14284A/xx unknown
-
1985
- 1985-10-03 US US06/783,686 patent/US4721711A/en not_active Expired - Fee Related
-
1988
- 1988-08-18 AU AU21421/88A patent/AU652118B2/en not_active Ceased
-
1990
- 1990-11-19 SG SG936/90A patent/SG93690G/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI78691B (fi) | Foerfarande foer framstaellning av i position 3-substituerade pyridazinderivat, vilka inverkar pao det centrala nervsystemet. | |
US6514986B2 (en) | Chiral fluoroquinolone arginine salt forms | |
JP2019515024A (ja) | ボルチオキセチンのパモ酸塩及びその結晶形 | |
WO1999052525A1 (es) | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos | |
US20160368897A1 (en) | Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and Uses | |
WO2010043515A1 (en) | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides | |
CA2412164C (en) | Amidine derivatives as selective antagonists of nmda receptors | |
JPH0367071B2 (sv) | ||
AU2001264116A1 (en) | Amidine derivatives as selective antagonists of NMDA receptors | |
KR20170133493A (ko) | A2b 길항제로서 크산틴-치환된 알키닐 카르바메이트/리버스 카르바메이트 | |
NO840329L (no) | Fremgangsmaate for fremstilling av 4-cyanopyridazin-derivater. | |
BR112020001775A2 (pt) | composto e processo para a preparação do mesmo, composição farmacêutica. | |
IE840102L (en) | Diazine derivatives | |
CN101209994B (zh) | 选择性m4受体拮抗剂及其医药用途 | |
PT78491B (en) | Process for the preparation of new 5-acyl-2-(1h)-pyridinones useful as cardiotonic agents | |
CZ265498A3 (cs) | Triazolové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem | |
WO2022022388A1 (zh) | 一种地佐辛衍生物晶型a及其制备方法和应用 | |
BR112020008371A2 (pt) | novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor | |
HU190710B (en) | Process for preparing 2-/4-piperazinyl/-4-phenyl-quinazoline derivatives | |
JP2010529093A (ja) | 1−ベンジルピラゾール誘導体、その調製方法および治療的使用 | |
WO2013093458A2 (en) | Antiviral drug derivatives | |
WO2013066834A1 (en) | Compounds and methods | |
JPH10237028A (ja) | Nos阻害作用を有する芳香族アミン誘導体 | |
JP3504972B2 (ja) | 2−[2−(置換アミノ)ベンジルチオ]−5,6,7,8−テトラヒドロピリド[3,4−d]ピリミジン−4(3H)−オン誘導体 | |
WO2022087433A1 (en) | Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Patent lapsed | ||
MM | Patent lapsed |
Owner name: SANOFI |